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2 
Structured Summary (248 words) 25 
Aim:  Internationally, health technology assessments (HTAs) are ubiquitous drivers to health policy. Within 26 
Scotland, the Scottish Medicines Consortium undertakes the medicine review process.  Input from clinical 27 
experts, involved in frontline care, is an integral component of the assessment process. This paper explores 28 
the relationship between the clinical experts and the HTA agency within Scotland to better understand what 29 
motivates expert clinicians to devote their time to the medicine review process with no remuneration.  30 
 31 
Methods:  27 clinical experts from 16 different clinical specialties took part in one-to-one interviews at their 32 
place of work between October 2011 and March 2012. Data analysis was inductive and comprised the 33 
organisation of data into a framework and a subsequent thematic analysis.  34 
 35 
Results: Three distinct themes were identified: (1) recruitment which identified two types of explanations for 36 
the ĞǆƉĞƌƚƐ͛ appointment: external justification (nominated by another) and internal justification (being 37 
recognised as an expert); (2) flexibility of the procedures, with experts able to determine their own response 38 
style and negotiate timelines; (3) healthcare systems, demonstrating that their affiliation to the health system 39 
underpinned the relationship and their motivation to be clinical experts. 40 
 41 
Conclusions: The findings of this study provide insight into the elements important to clinicians who 42 
voluntarily contribute to HTA processes.  Examination of these elements in the context of the organisational 43 
citizenship behaviours (OCB) literature provides a foundation on which to improve understanding of this 44 
relationship and sustain and improve clinical expert participation in an increasingly intensified clinical 45 
environment and within cash-limited HTA systems. 46 
 47 
 48 
 49 
 50 
 51 
 52 
3 
Introduction  53 
 54 
Health technology assessment (HTA) is a multidisciplinary activity that scrutinises the safety, clinical and cost-55 
effectiveness of health technologies including medicines [1, 2].  The aim of HTA is to provide evidence-based 56 
information to inform the use of health technology and allocation of resources. The 1980s and 1990s saw a 57 
proliferation in the number of European HTA organisations, with the first HTA agencies appearing in France, 58 
Spain and Sweden. This was followed by the Netherlands, Austria, Finland, Latvia, Denmark, Norway, Germany 59 
and the United Kingdom[3]. By 2008, 16 European countries had formal HTA organisations[4, 5] and today the 60 
number of HTA agencies continues to grow across Europe [6].  61 
 62 
The structure, role and processes of HTA agencies vary between countries but can broadly be divided into 2 63 
groups: (1) agencies providing an advisory or regulatory function, often aligned to re-imbursement; and (2) 64 
independent review agencies generating HTAs to support clinical practice decisions [1]. For example, in France 65 
and Sweden, HTA is used to support reimbursement decisions while, in Scotland, the Scottish Medicines 66 
Consortium (SMC) provides advice to the National Health Service (NHS) about the comparative clinical and 67 
cost-effectiveness of medicines.  Similar to SMC, the National Institute for Health and Care Excellence (NICE) 68 
provides advice on new medicines to the NHS in England in addition to clinical guidelines, social care guidance, 69 
and interventional procedures guidance. 70 
 71 
Good practice for HTA dictates that key stakeholders who may be impacted by the HTA decision must be 72 
engaged with in order to improve the quality, relevance and acceptability of HTA [7, 8]. Failure to do so may 73 
delay implementation of HTAs due to appeals and disagreement amongst stakeholders [1]. Stakeholders vary 74 
according to the role of the HTA agency but often include policy makers, health professionals, patients, and 75 
industry [9]. Of these stakeholders, health professionals are of particular importance as they may be involved 76 
at a number of stages in the HTA process: topic nomination, review of the evidence, development of the HTA 77 
report or appeal of the HTA decision [10].  78 
 79 
 80 
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In Scotland, the SMC recruits healthcare professionals as clinical experts. These are consultant physicians, 81 
surgeons, specialist pharmacists and general practitioners who are contacted at the beginning of the medicine 82 
assessment process. The clinical experts  provide contextual information on current prescribing practice, 83 
disease prevalence, unmet clinical need and product fit within clinical practice[11] and gives a vital opinion 84 
about a proposed new mediĐŝŶĞ͛Ɛ use ͞Ăƚ the coal-ĨĂĐĞ͟. However, this is not an explicit part of the ĐůŝŶŝĐŝĂŶ͛Ɛ 85 
professional role, offers no remuneration or direct reward, and is voluntary with limited external pressure as 86 
the recruitment process is anonymous. The need to understand the mechanisms behind this behaviour is two-87 
fold. Firstly, by developing an understanding of the relationship, clinical expert input to the medicine review 88 
process may be sustained and even increased within HTA generally. Secondly, due to the financial limitations 89 
within which all health care providers operate, through understanding the dynamics within the SMC it may be 90 
possible to export the model of voluntary clinician engagement into other healthcare activities.  91 
 92 
 No research within health care has examined this relationship in HTAs but the field of psychology could 93 
provide a framework from which to consider ĐůŝŶŝĐŝĂŶƐ͛ engagement. Organisational citizenship behaviour 94 
(OCB) is defined as ͞individual behavior that is discretionary, not directly or explicitly recognized by the formal 95 
reward system, and in the aggregate promotes the efficient and effective functioning of the organization͟[12]. 96 
Organ and colleagues propose five dimensions within OCB: altruism, courtesy, conscientiousness, civic virtue, 97 
and sportsmanship [12].  These dimensions are widely used within the literature, although not universally 98 
accepted [for example 13], and offer a basis from which to explore clinician engagement within HTAs. For our 99 
purposes ͞ĐŝǀŝĐ virtue" is most relevant as it includes organisationally focused behaviours such as the 100 
attendance of  non-mandatory meetings, an interest in the organisation and improving its performance, and 101 
the willingness of the employee to share their experience and knowledge with others[14, 15]. Two distinct, 102 
but related, forms of civic virtue (CV) OCBs have been proposed ʹ information gathering (CV- information) and 103 
influence exercising (CV-influence) [16].  While CV-information focuses on activities such as attendance at 104 
meetings and keeping up to date, CV-influence includes suggesting change within an organisation [16].  105 
 106 
To the ĂƵƚŚŽƌƐ͛ knowledge, there has been no research examining OCBs within the HTA process but it may be 107 
that this model, and the associated research, provides a basis for understanding the behaviour ʹ and how to 108 
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promote it. It is important that the mechanisms for this behaviour be understood within a HTA context, where 109 
clinicians include world leaders within their fields and therefore their involvement in medicine review 110 
processes is not just desirable but necessary. To this end an exploratory, qualitative evaluation was 111 
undertaken to examine why the clinical experts engaged and supported the medicine review process.   112 
 113 
METHODS  114 
Ethical Approval   115 
The project was a service evaluation and therefore did not require University of Strathclyde ethical approval 116 
[17, 18].  Additionally, NHS ethical review under the terms of the Governance Arrangements for Research 117 
Ethics Committees (REC) in the UK was not required as the project is an opinion survey seeking the views of 118 
NHS staff on service delivery (as advised by the East of Scotland NHS Research Ethics Service).  119 
 120 
Materials  121 
A semi-structured interview schedule was developed through discussions within the multidisciplinary 122 
evaluation team (comprising pharmacists, social scientists, medical clinician, and information analyst) and the 123 
ĞǀĂůƵĂƚŝŽŶ͛Ɛ steering group. It was designed to capture a wide range of experiences and areas of interest 124 
around the role of the clinical expert. The schedule was piloted with a clinical expert and amendments were 125 
made as necessary (this participant was not included in the final sample). See supporting information for the 126 
schedule.  127 
 128 
Procedure  129 
The SMC provided details of their clinical experts (n=450) and an email was sent alerting them to the 130 
evaluation and inviting them to take part through return email. Fifty-four (12%) responded positively to the 131 
request. A purposive sampling strategy was devised to retain the proportions of profession, specialty and 132 
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geography of the respondents (see Table 1). A total of 30 participants were selected as it was viewed that this 133 
would be sufficient for saturation of data (i.e. no new themes would emerge in subsequent interviews).  134 
[insert Table 1 around here] 135 
One-to-one interviews were conducted at each clinical ĞǆƉĞƌƚ͛Ɛ place of work during office hours over the 136 
period between October 2011 and March 2012. Participants read an information sheet detailing what the 137 
study would involve, that the interview data would be anonymised and their participation was entirely 138 
voluntary. All participants signed the consent form provided by the researcher. All interviews were conducted 139 
by EDC, lasted between 30 and 90 minutes, were recorded using a Dictaphone and transcribed verbatim. A 140 
framework analysis was applied to the data, allowing the analysis of main themes to be carried out on a large 141 
volume of data [19, 20].  RN and EDC coded the data, then met and examined their developed thematic 142 
framework and coded data; areas of disagreement were resolved through consensus.   These codes were then 143 
organised in order to develop themes and sub-themes by EDC.  144 
 145 
 146 
RESULTS 147 
 148 
Participants 149 
 150 
Of the 30 clinical experts who had agreed to take part, three dropped out of the study prior to 151 
commencement of the interviews. The remaining 27 participants ranged in age from 32 to 63 years (median = 152 
48, IQR= 46-53). A third of the sample were female and participants had been clinical experts for between 6 153 
months to 10 years (median= 5, IQR= 3-7), and had given advice on between 2 and 60 medicines (median= 5, 154 
IQR= 3-10).  Two participants had previously been members of the SMC.  Participants represented 16 different 155 
medical/surgical specialties: oncology/haematology (n=6), anaesthetics (n=3), genitourinary /obstetrics and 156 
gynaecology (n=2), neurology (n =2), psychiatry/mental health (n=2), infectious diseases (n=2) and one 157 
7 
representative each from paediatrics, cardiology, orthopaedics, general medicine, rheumatology, 158 
endocrinology, biochemistry, ophthalmology, nephrology and liver transplant/surgical.    159 
 160 
Data Analysis  161 
 162 
Nine randomly selected interviews were read by two researchers who worked independently to derive 163 
frameworks of descriptive themes. These researchers then met and compared frameworks; disagreements 164 
were resolved through discussion. The remaining 18 interviews were coded and relevant quotes were selected 165 
and placed into the framework table and validated by a third researcher; additional quotes were added 166 
through discussion. This validated framework was summarised for the subsequent thematic analysis. 167 
The thematic analysis identified three distinct themes related to why the clinical experts participate in the 168 
medicine review process: (1) recruitment; (2) flexibility of procedure; and (3) healthcare  systems. Sub themes 169 
within these themes are explored and quotes are used to accompany these. Hesitations have been removed 170 
and, on occasion, words contained in parentheses have been added to clarify meaning or disguise any 171 
identifying information.  Text that has been removed is represented by ellipses.  Accompanying each quote, in 172 
brackets, are the ƉĂƌƚŝĐŝƉĂŶƚ͛s professional title and clinical expert experience. In general, the themes were 173 
expressed in the majority of the interviews unless stated otherwise. The supporting quotes are presented in 174 
Figure 1.  175 
[Insert Figure 1 around here] 176 
Theme 1: Recruitment     177 
Only one clinical expert reported actively volunteering for the role. Many clinical experts were not entirely 178 
sure how they had assumed the role as clinical expert, only that they were approached. Two types of 179 
explanations for recruitment were identified: external justifications (recruited or nominated by others) and 180 
internal factors (recruited as a result of clinical experience). Both patterns of justification suggested that being 181 
8 
considered an expert in a field ʹ either by ŽŶĞ͛Ɛ own opinion or through the nomination of others ʹ may be 182 
crucial in engaging the help of the clinical experts. 183 
External Justification 184 
Most participants reported being approached by SMC to become a clinical expert and either suspected or 185 
knew they had been nominated by colleagues, or identified through various committees they had been 186 
involved in (Quotation 1). In these cases, participants were often not fully aware of who had nominated them, 187 
and they often assumed that they were identified through these channels, with some even stating that they 188 
were never ͚ĨŽƌŵĂůůǇ ĂƉƉŽŝŶƚĞĚ͛ and had been involved almost by default (Quotation 2).  189 
 190 
Internal Justification 191 
Some participants reported that they had been recruited as clinical experts due to their level of involvement 192 
and expertise in their specialist field rather than referring to a nominator (Quotation 3).  193 
Theme 2: Flexibility  194 
Flexibility in Response Style 195 
The way that clinical experts approached providing their advice on new medicines varied. Some experts felt 196 
that extra reading was required before giving advice (Quotation 4) whereas others felt that, as an ͞expert͕͟ 197 
their opinion should be informed enough to provide an appropriate and extensive answer. Additionally, the 198 
SMC was reported to give limited guidance regarding the length/focus of responses. This promoted the 199 
ĞǆƉĞƌƚƐ͛ autonomy, allowing their response style to vary depending on the individual clinician (Quotation 5). 200 
However, some clinicians voiced a preference for the SMC to provide them with guidance on the length/focus 201 
of response, and feeling confused around how extensively their answers should be researched (Quotation 6). 202 
Some participants did identify that there was probably a good reason behind not guiding or influencing clinical 203 
experts responses, as the SMC would be looking for an individual ĐůŝŶŝĐŝĂŶ͛Ɛ view rather than one influenced by 204 
external factors such as other expert advice. Many observed that the SMC did ask additional questions if their 205 
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answers had been lacking somehow, and assumed that if they ĚŝĚŶ͛ƚ hear otherwise from the SMC and they 206 
were asked to provide advice again that they must be fulfilling their role adequately as an advice-provider.  207 
Flexibility of Engagement Style 208 
Many participants expressed that, although they felt more informed about SMC process since becoming a 209 
clinical expert, they still lacked knowledge around what the whole process involved, where they fitted into the 210 
process and what contribution their advice actually made to the final decision (Quotation 7). Although some 211 
were comfortable with the remote engagement style, many felt that their need to be fully involved and 212 
engaged with the SMC would be fulfilled if they were provided with more information and two-way feedback 213 
on the full extent of the role clinical experts were expected to play. 214 
All participants reported being contacted via email whenever SMC requested their advice, with only a few 215 
speaking to an SMC staff member over the phone (this kind of interaction was usually initiated by the clinical 216 
expert). The advantage of emails was that they could be stored and responded to when convenient (Quotation 217 
8) but some clinical experts expressed that they would appreciate more direct communication from the SMC, 218 
with the possibility for more involved engagement (Quotation 9). Little feedback was received by the clinical 219 
experts on the advice that they provided or information on the decision made by the SMC. Participants 220 
indicated that they usually became aware of the SMC decision through other routes (Quotation 10). 221 
Flexibility of Response Time 222 
Clinical experts reported that providing advice could be limited, and in some cases not possible, due to 223 
time restrictions. Participants also reported that SMC were very accommodating when time was an 224 
issue, and would often negotiate a more suitable date by which to provide their advice. This flexible ͚ŶŽ-225 
ƉƌĞƐƐƵƌĞ͛ approach may be attractive to busy experts, and thus motivate them to continue involvement 226 
with the SMC (Quotation 11).  Some participants reported suggesting other colleagues to the SMC in the 227 
event that they could not provide advice within the timelines or considered that another person may be 228 
more appropriate.   229 
Flexibility in what motivates a clinical expert 230 
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When asked what the benefits were of being a clinical expert, participants reported personal, internal and 231 
external motivators for responding to requests for advice. One important set of benefits mentioned were the 232 
personal development and learning opportunities associated with the role (Quotation 12). Responses ranged 233 
from participants finding it ͞interesting͟ and beneficial in keeping up-to-date on a scientific and clinical level; 234 
to others stating that it was important in alerting them to potential new medicines becoming available. Others 235 
felt a sense of personal satisfaction and prestige associated with the role. Many reported that it was rewarding 236 
to be recognised as an expert, by the SMC and by their peers, and to feel that they were one of the best 237 
informed in their particular field (Quotation 13). Some reported feeling more informed about the SMC in 238 
general, and feeling informed not only brought a sense of satisfaction, but being privy to the new medicines 239 
review process gave some participants confidence that the process was transparent and fair. Participants also 240 
reported the benefits of being able to see the impact of their advice when it was reflected in SMC decisions 241 
and guidance. The opportunity to influence SMC decisions was reported by many participants as a benefit of 242 
responding to requests for advice. Some saw it as a chance to impact upon prescribing behaviours and 243 
practice at a national level, which in turn made them feel part of national decision making in addition to their 244 
local NHS Board role (Quotation 14). These personal, internal and external motivators all provide insight as to 245 
why clinical experts volunteer their time to the SMC. 246 
Theme 3: Healthcare Systems 247 
The profile of the SMC within NHS Scotland 248 
The relevance of the ^D͛Ɛ decisions to the ĐůŝŶŝĐŝĂŶƐ͛ professional roles was recognised and overall the SMC 249 
was viewed positively. When asked their opinions of the SMC and why participants volunteered their time for 250 
them, the general consensus was that the organisation was valued (Quotation 15).  Many reported trusting 251 
the SMC, having confidence in them and believing that they operated in a useful and fair manner, improving 252 
year upon year. Many also reported the benefits of the ŽƌŐĂŶŝƐĂƚŝŽŶ͛Ɛ speed in making decisions, and praised 253 
their ability to provide clear and concise advice for clinicians (Quotation 16). The SMC was seen as 254 
approachable, and clinical experts felt valued in their role and praised the SMC for consulting clinicians whose 255 
prescribing practices would be directly affected by the outcome of the medicine review process (Quotation 256 
17).  257 
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The relevance of the SMC within professional Role 258 
Many participants reported seeing the relevance of being a clinical expert to their current professional role 259 
and volunteering as a clinical expert was a natural progression (Quotation 18). For some, being a clinical 260 
expert fell under the realm of professional activities expected of them as clinicians. Others also saw 261 
contributing to SMC processes as part of their continuing professional development (CPD) which all clinicians 262 
are required to record (Quotation 19). Engaging with the SMC as a clinical expert, therefore, provided some 263 
personal professional opportunities. Furthermore, some reported that being a clinical expert made them more 264 
aware of SMC guidance and more likely therefore to adhere to it. Additionally, participants commented on 265 
how being a clinical expert supported the ĐůŝŶŝĐŝĂŶ͛Ɛ role of helping and representing patients (Quotation 20). 266 
Some also saw being an expert advisor to the SMC as an opportunity to be more privy to information about 267 
new medicines, and this was important in managing patient care and expectations more effectively (Quotation 268 
21). 269 
 270 
DISCUSSION 271 
The importance of engaging clinical experts in the HTA process is well recognised internationally[1, 7, 8, 10]   272 
but  we found no published evidence on why experts engage and how this can be sustained and improved, 273 
particularly in an increasingly intensified clinical practice environment. This study identified three key themes 274 
that underpin why clinicians volunteer their time to HTA agencies: recruitment; flexibility of the procedures; 275 
and, the profile and relevance of the  SMC within the health care system.  276 
The current ƐƚƵĚǇ͛Ɛ findings resonate with some of the OCB literature. Firstly, taking part in HTA was 277 
rewarding to the expert, although the exact reward depended on the individual. This is in line with literature 278 
reporting that helping behaviours, such as those seen with OCBs, are associated with positive consequences 279 
such as self-development or feelings of well-being [21]. Rewards such as seeing the results of their advice and 280 
the national impact suggest that clinical experts see the meaningfulness of their contribution. An ĞŵƉůŽǇĞĞ͛Ɛ 281 
perception of their work as being significant has been positively linked to civic virtue behaviour which aims to 282 
change the way of working within an organisation (CV-influence)[16].Secondly, some clinicians viewed this 283 
role as an extension to their professional role and that they had a moral responsibility to their patients to 284 
12 
engage in this process. Expressions of OCBs are not always seen by employees as being discretionary [22] and 285 
moral obligations are thought to be consistent with OCBs [12]. Thirdly, the clinical experts appeared positive 286 
about SMC, and by association the NHS. ŵƉůŽǇĞĞƐ͛ perception of their organisation as being fair was an 287 
important determinant for OCBs [23], while commitment to the organisation was seen to predict civic virtue 288 
behaviours such as keeping up to date (CV-information) [16]. 289 
How an HTA agency engages their clinical experts is therefore likely to underpin ĞǆƉĞƌƚƐ͛ level of commitment 290 
to the HTA process. The flexibility offered by the SMC, such as with response style and timescales, may 291 
decrease obstacles to the clinicians͛ involvement in the HTA process.  A The SMC engaged directly with the 292 
clinical experts and provided flexibility in response style and time, which were both highly valued by the 293 
experts. However, the clinical experts voiced that they would welcome increased two-way feedback on their 294 
input and the final decision made by the SMC.  An investigation undertaken by an HTA organisation in the USA 295 
found that a common complaint among stakeholders was the lack of response to written comments submitted 296 
[10].  297 
Outwith new medicines assessment, the wider clinical guideline development community ʹ for example SIGN 298 
and NICE ʹ recognise the importance of expert healthcare provider engagement[24, 25]. However, there 299 
remains limited evidence on why they engage and how this is sustained. Consideration of the OCB framework 300 
could support the wider engagement of expert clinicians across the HTA portfolio. 301 
 302 
Study Strengths and Limitations 303 
Participants self-selected into the study, which might imply that these experts were not representative of the 304 
group as a whole. It must be recognized that the motivations to reply to the recruitment email may be similar 305 
to those that drive involvement with the SMC and the experts who did not reply may represent a distinct 306 
group with differing views of SMC engagement.  However, the experts interviewed were a heterogeneous 307 
sample from sixteen different specialties with a broad range of experiences in the role. It is recognized that by 308 
choosing to retain the geographical distribution of our original sample, we ͞ůŽƐƚ͟ potential participants from 309 
three additional specialties (respiratory, prescribing support and colorectal). Motivations within clinicians who 310 
work in different clinical specialities may be more different than the motivations between NHS board 311 
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employees, although there was agreement across the specialties included in our sample. Clinical experts who 312 
no longer gave advice, and their reasons for this were not included in this sample, but it would be important 313 
for further exploration to involve such experts.  314 
 315 
The issue of generalisability within qualitative research is an important one.  For exploratory analysis such as 316 
this, interviews give insight to the issues most relevant to the group being interviewed.  However, the themes 317 
derived from the data reflected the fact that there were many commonalities in their experiences with being a 318 
clinical expert, and the lack of new emerging themes as the interviews progressed over time suggested that 319 
saturation was reached (i.e. further interviews would not have resulted in additional themes). The extent to 320 
which these findings are generalisable between countries is as yet poorly understood ʹ although the OCB 321 
literature suggests that cultural differences, for example between collectivist and individualist cultures, are 322 
important  within organisations [12]-  and would benefit from further research. 323 
Future Directions 324 
Evidence suggests that organisations can improve their performance by encouraging OCBs[26].This project has 325 
revealed the importance of autonomy, flexibility and awareness of the relevance of work to the national 326 
agenda in explaining why clinical experts take part in the medicine review process.  Balancing this with a call 327 
from clinical experts for increased engagement (guidance on their role and feedback on their inputs) poses 328 
challenges for any HTA; there is a balance to be struck between potential improved quality and 329 
standardisation of responses through more directive guidance from HTAs and the potential perception, real or 330 
not, of increased workload and reduced flexibility impacting on expert retention.   Examining future 331 
engagement enhancement initiatives through the lens of the OCB literature is a first step in understanding 332 
how OCBs can be contextualised within healthcare as an enabler to capitalise on ĐůŝŶŝĐŝĂŶƐ͛ expertise.    333 
Further research should focus on how to maximise clinical expertise in vital health systems locally, nationally 334 
and internationally through a growing understanding of OCB within these different healthcare settings.  The 335 
result will be the development of an evidence base on how HTAs may best engage this important stakeholder 336 
group in their decision making processes.      337 
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TABLE LEGEND 448 
 Table 1. Comparison of the medical specialty of SMC experts who agreed to be involved in the study with 449 
those who were finally recruited. 450 
 451 
 452 
Medical Specialty All Respondents Total (%) Participants Total (%) Difference (%) 
Oncology/Haematology 12 (22.2%) 6 (22.2%) 0 
Anaesthetics 8 (14.8%) 3 (11.1%) -3.7% 
Genitourinary /OBGYN 6 (11.1%) 2 (7.4%) -3.7% 
Neurology 4 (7.4%) 2 (7.4%) 0 
Psychiatry/Mental Health 4 (7.4%) 2 (7.4%) 0 
Infectious Diseases 2 (3.7%) 2 (7.4%) +3.7% 
Paediatrics 1 (1.9%) 1 (3.7%) +1.8% 
Cardiology 1 (1.9%) 1 (3.7%) +1.8% 
Orthopaedics 1 (1.9%) 1 (3.7%) +1.8% 
General Medicine 4 (7.4%) 1 (3.7%) -3.7% 
Rheumatology 1 (1.9%) 1 (3.7) +1.8% 
Endocrinology 1 (1.9%) 1 (3.7) +1.8% 
Biochemistry 1 (1.9%) 1 (3.7) +1.8% 
Ophthalmology 2 (3.7%) 1 (3.7%) 0 
Nephrology 1 (1.9%) 1 (3.7) +1.8% 
Liver Transplant/Surgery 1 (1.9%) 1 (3.7%) +1.8% 
Respiratory 2 (3.7%) 0 -3.7% 
Prescribing Support 1 (1.9%) 0 -1.9% 
Colorectal 1 (1.9%) 0 -1.9% 
 453 
 454 
 455 
FIGURE LEGEND 456 
Figure 1: Themes and quotations arising from clinical expert interviews 457 
Theme 1: Recruitment 458 
External Justification 459 
1. I think one of my colleagues must have nominated me. Because I just got an email so I suspect because the 460 
people I share an office with ͙ I presume it was [my colleague] that nominated me (Clinical Effectiveness 461 
Pharmacist, clinical expert for 4 years) 462 
18 
2. I think I just got emailed ... they send out the email and say, ͞o you know anything about this drug? Do 463 
you feel confident in giving us an opinion on this drug͍͟ ͙ďƵƚ there's never been an actual formal 464 
appointment (Consultant, clinical expert for 7 years) 465 
Internal Justification 466 
3. I͛ǀĞ worked in [specialty] for 15/20 years now since-since qualifying, /͛ǀĞ been involved since 1990 467 
(Consultant, clinical expert for 2 years) 468 
 469 
Theme 2: Flexibility  470 
Flexibility in Response Style 471 
4. It͛Ɛ worth just checking what the current clinical guidelines are and saying well, this medicine fits in to that 472 
gap, or alternatively, there is no place for this particular drug... So it involves some reading around the 473 
subject (Consultant, clinical expert for 10 years) 474 
5. It does depend on how much work you feel you've to put into it personally ͚ĐĂƵƐĞ if you feel you've got to 475 
go off and do a literature search on it, but ƚŚĂƚ͛Ɛ never the approach I've taken.  (Consultant, clinical 476 
expert for 3 years) 477 
6. I answer the email in a particular way but I don't know if what I'm doing is one hundred per cent   correct... 478 
so there is I suppose a lack of two-way feedback (Consultant, clinical expert for 7 years) 479 
 480 
Flexibility of Engagement Style 481 
7. Interviewer: So you ĚŽŶ͛ƚ know anything that happens [with your advice]? 482 
                Clinical expert: Not a clue... ΀/ƚ͛Ɛ΁ a bit like leaving an exam without a mark (Consultant, clinical expert for 483 
7 years) 484 
8. I'm quite happy to be contacted in the way that I'm contacted and email seems quite convenient really 485 
(Consultant, clinical expert for 7 years) 486 
9. I͛ǀĞ certainly never been to anything ...they are a little bit distant. (Consultant, clinical expert for 10 years) 487 
10. It would be useful for them to feedback the guidance once it's public ...directly to us rather than having to 488 
wait to hear (Consultant, clinical expert for 3 years) 489 
 490 
Flexibility of Response Time 491 
11. I͛ǀĞ missed it, because I was away on holiday ͙ so I͛ǀĞ just emailed back and said, ͚I͛ŵ sorry, I was away, 492 
/͛ǀĞ missed the ĚĂƚĞ͕͛ so ƚŚĞǇ͛ǀĞ then emailed back and said, ͚tĞůů͕ can you send your response ĂŶǇǁĂǇ͍͛ 493 
(Consultant, clinical expert for 6 years) 494 
  495 
Flexibility in what motivates a clinical expert 496 
12. It actually makes me think that, you know, there are new drugs out there. It makes me do the work and 497 
trawl through the literature ͙ it keeps you in tune of ǁŚĂƚ͛Ɛ coming out (Consultant, clinical expert for 7 498 
years) 499 
13. I͛ŵ happy to do it... everyone wants to be an expert, ĚŽŶ͛ƚ they? You know, ƚŚĂƚ͛Ɛ like a pat on the head. 500 
(Consultant, clinical expert for 6 years) 501 
14. It should give me a way to influence their decisions (Consultant, clinical expert for 10 years) 502 
 503 
Theme 3: NHS Systems 504 
The profile of SMC within NHS Scotland 505 
15. I think ŝƚ͛Ɛ quite nice to have a Scottish organisation taking advice from Scottish experts and producing its own 506 
opinions, and I do think ŝƚ͛s valuable.(Consultant, clinical expert for 5 years) 507 
16. I think it's excellent and the summaries they provide, the assessment of products are very clear, 508 
comprehensive - they give good guidance, they're timely.(Principal Pharmacist, clinical expert for 5 years) 509 
17. I suppose benefits to the services that I see is ŝƚ͛Ɛ very useful that they get real life feedback on what 510 
happens in practice rather than just from reading the papers that the company have submitted or 511 
whatever.(Clinical Effectiveness Pharmacist, clinical expert for 4 years) 512 
 513 
The relevance of SMC within Job Role 514 
18. I think this is, in a way, part of our ũŽď͙ we all have a professional responsibility to practice cost- 515 
effectively, and also to advise colleagues, because, you know, as specialists in the field, we then need to 516 
advise, for example, general practitioners. (Consultant, clinical expert for 1 year) 517 
19. I obviously take part in continual professional development, and I do read articles/ literature ͙/ think you 518 
focus more if ǇŽƵ͛ƌĞ being asked to give an expert opinion because you realise ƚŚĞƌĞ͛Ɛ a responsibility to 519 
this(Consultant, clinical expert for 1 year) 520 
20. It͛Ɛ a little bit altruistic that you do it for the greater good...if you become a senior consultant or if you become an 521 
expert in the field, ŝƚ͛Ɛ part of the payback (Consultant, clinical expert for 10 years) 522 
19 
21. Engagement with the SMC allows me to feel that I'm contributing to the availability of exciting new [specialty] 523 
drugs for my patients. dŚĂƚ͛Ɛ what ŝƚ͛Ɛ all about (Medical Practitioner, clinical expert for 5 years) 524 
 525 
